SCHEMBL18044579

SCHEMBL18044579

Cn1cc(-c2ccc(NC(=O)c3cc4c(n(-c5ccccc5)c3=O)CCCC4=O)nc2)c2c(Cl)ncnc21

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.67
▸ USP2 O75604 2/20 0.67
▸ TSHR P16473 2/20 0.67
▸ KDM4E B2RXH2 5/20 0.63
▸ ALDH1A1 P00352 4/20 0.63
▸ PKM P14618 2/20 0.63
▸ MAPT P10636 2/20 0.63
▸ HPGD P15428 2/20 0.63
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ AXL P30530 6/20 0.52
▸ MERTK Q12866 5/20 0.52
▸ HTT P42858 1/20 0.48
▸ TP53 P04637 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.43
▸ TYRO3 Q06418 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16709489 0.91 ALDH1A1 (0.63) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044730 0.90 ALDH1A1 (0.61) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044591 0.87 ALDH1A1 (0.56) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044596 0.84 AXL (0.55) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL16709454 0.82 TYRO3 (0.57) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044540 0.81 ALDH1A1 (0.52) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044583 0.81 TYRO3 (0.55) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044534 0.81 USP2 (0.49) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044577 0.80 ALDH1A1 (0.48) HSD17B10USP2TSHRKDM4EALDH1A1
SCHEMBL18044581 0.80 ALDH1A1 (0.57) HSD17B10USP2TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3067356-B1 PYRROLO PYRIMIDINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2018-07-04 — — EP disclosed
US-9586967-B2 Pyrrolo pyrimidine derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2017-03-07 — — US disclosed
US-20160264579-A1 PYRROLO PYRIMIDINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2016-09-15 — — US disclosed
EP-3067356-A1 PYRROLO PYRIMIDINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2016-09-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264579-A1 PYRROLO PYRIMIDINE DERIVATIVE AXL, FLT3, TYRO3 HSD17B10 4559/4885USP2 3733/4885TSHR 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback